Ensysce Biosciences Inc

ClearOne, NeOnc Technologies, Iovance Biotherapeutics, and Ensysce Biosciences each reported significant clinical, regulatory, or financial developments. ClearOne moved closer to completing its acquisition of Cortigent, a neurotechnology subsidiary of Vivani Medical, after majority shareholder First Finance Ltd., which controls approximately 61.3% of voting power, approved the transaction and the issuance of 12.5 million shares. NeOnc Technologies is approaching topline Phase 2a data from its fully enrolled NEO100-01 study and has expanded internationally with a second IND authorization from Abu Dhabi for recurrent high-grade gliomas. Iovance Biotherapeutics reported record second-quarter 2026 revenue of approximately $99.3 million, a 66% year-over-year increase driven by its FDA-approved TIL therapy Amtagvi, and is reviewing its 2026 revenue guidance of $350 million to $370 million. Ensysce Biosciences acquired privately held Cy Biopharma, adding the clinical-stage neuroplastogenic therapy CY200 for Complex Regional Pain Syndrome Type 1, and secured financing that could total up to $77 million, including $17.1 million in cash and a $21.5 million private placement led by Ally Bridge Group.

A new report titled "Postoperative Pain - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com, offering critical insights into over 40 companies and 50 pipeline drugs shaping the postoperative pain landscape. The report features comprehensive profiles of drugs in various phases, from clinical to nonclinical stages, including late-stage candidate PF614 from Ensysce Biosciences, an oxycodone-based medication currently in Phase III trials. Mid-stage products include ATX101 from Allay Therapeutics, a sodium ion channel blocker and biopolymer combination in Phase II for extended relief post knee arthroplasty, and LC-400 from LipoCure, an ultra-long-acting local anesthetic advancing to Phase II. Early-stage highlights feature GB-6002 from G2GBIO, an extended-release ropivacaine injectable in Phase I promising over three days of pain relief with a single dose. The report also covers therapeutic assessment by route of administration, molecule type, and development stage, along with pipeline development activities such as collaborations and licensing.